Last reviewed · How we verify
Cesamet
At a glance
| Generic name | Cesamet |
|---|---|
| Sponsor | Veeda Oncology |
| Target | Cannabinoid receptor 2, Cannabinoid receptor 1, Cannabinoid receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Chemotherapy-induced nausea and vomiting
Common side effects
- Drowsiness
- Vertigo/Dizziness
- Euphoria
- Dry Mouth
- Ataxia
- Visual Disturbance
- Concentration Difficulties
- Depression
- Headache
- Hypotension
- Asthenia
- Anorexia
Serious adverse events
- Cerebral vascular accident
- Syncope
- Arrhythmia
- Convulsions
- Hallucinations
- Vomiting
- Tachycardia
- Orthostatic hypotension
- Palpitation
- Dystonia
Key clinical trials
- The Role of Endocannabinoids in Insulin Production and Action (PHASE1)
- Investigating the Effects of Nabilone on Endocannabinoid Metabolism (PHASE4)
- Nabilone for Agitation Blinded Intervention Trial (PHASE3)
- Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities (PHASE1)
- Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury (PHASE3)
- Nabilone for Agitation in Frontotemporal Dementia (PHASE2)
- Effect of PP-01 on Cannabis Withdrawal Syndrome (PHASE2)
- Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cesamet CI brief — competitive landscape report
- Cesamet updates RSS · CI watch RSS
- Veeda Oncology portfolio CI